Update shared on 20 Nov 2025
Analysts have maintained their target price for Embla Medical hf. at €37.40, citing minor adjustments to discount rates and future market assumptions, but no significant change in company fundamentals.
What's in the News
- Opened a new prosthetic clinic in Kyiv and launched the "Iceland Supports Mobility in Ukraine" three-year initiative to deliver prosthetic care and rehabilitation to up to 1,000 Ukrainian amputees, in partnership with the Government of Iceland and Future for Ukraine. The initiative is valued at USD 11 million. (Key Developments)
- Reiterated earnings guidance for the full year 2025 and maintained expectations of 5-6% organic sales growth. (Key Developments)
- Completed a share buyback tranche and repurchased a total of 1,449,010 shares for $7 million under the ongoing program. (Key Developments)
Valuation Changes
- Fair Value is unchanged at €37.40 per share.
- The discount rate increased slightly from 7.24% to 7.42%.
- Revenue growth is essentially flat, remaining at approximately 9.45%.
- Net profit margin is marginally lower, moving from 10.65% to 10.63%.
- The future P/E ratio has risen slightly from 24.32x to 24.62x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.